Avisa Diagnostics Inc.

Effective immediately, the following companies are suspended pursuant to CSE Policy 3. The suspensions are considered Regulatory Halts as defined in National Instrument 23-101 Trading Rules. Cease Trade Orders have been issued by one or more securities commissions.

14/05/2021

2021-0515 – Changement Fondamental – FogChain Corp./Avisa Diagnostics Inc.

Le 14 mai/May 2021

Avisa Diagnostics Inc., the issuer resulting from a Fundamental Change of FogChain Corp. (FOG.X), has been approved for listing.

Listing and disclosure documents will be available at www.thecse.com on the trading date.

The Issuer offers an innovative approach to treating lung infections with rapid diagnostics to guide better clinical outcomes.

03/11/2020

2020-1102 - Changement de symbole - Désignation inactive - FogChain Corp (FOG)

Le 3 novembre/November 2020

The Exchange has determined that FogChain Corp. (the “Issuer”) has not met the continued listing requirements as set out in CSE Policy 2, Appendix A section 2.9.

Pursuant to Policy 6 section 2.4, the Issuer may not rely on confidential price protection, nor may the Issuer complete any financing without prior Exchange approval.

24/05/2018

2018-0522 – Nouvelle Inscription – FogChain Corp. (FOG)

Le 24 mai/May 2018

The common shares of FogChain Corp. have been approved for listing on the CSE.

Listing and disclosure documents will be available at www.thecse.com on the trading date.

Dépôts CSE

Fichier	Type	Date
MD&A for the quarter ended March 31, 2021 (Avisa Diagnostics)	MD & A (Discussion et analyse de la direction)	27/05/2021
MD&A for the quarter ended March 31, 2021 (Avisa Pharma)	MD & A (Discussion et analyse de la direction)	27/05/2021
Interim financial statements for the quarter ended March 31, 2021 (Avisa Diagnostics)	États financiers intermédiaires	27/05/2021
Interim financial statements for the quarter ended March 31, 2021 (Avisa Pharma)	États financiers intermédiaires	27/05/2021
Monthly Progress Report April 2021	Rapport d'activité mensuel	05/05/2021
December 31, 2020 MD&A	MD & A (Discussion et analyse de la direction)	30/04/2021
December 31, 2020 Audited Financials	États financiers annuels vérifiés	30/04/2021
Monthly Progress Report March 2021	Rapport d'activité mensuel	06/04/2021
Monthly Progress Report February 2021	Rapport d'activité mensuel	02/03/2021

Vous êtes ici